Aastha Gupta, Additional Director and Head of Hematopathology and Molecular Oncology at Fortis Memorial Research Institute, India, shared a post on LinkedIn:
“Extended immune subset analysis can reveal insights that routine tests often miss.
In one of our recent myelofibrosis cases on JAK inhibition (Jakavi), deep immunophenotyping showed a clear pattern: significantly reduced memory T-cell subsets with relatively preserved naïve resting T cells.
This helped explain the sustained therapeutic response to Jakavi—the drug’s action extends to immune subsets that drive chronic inflammation and disease activity. But it also highlighted a double-edged reality: suppressing memory T cells may support disease control, but at the same time it can also increase susceptibility to infections.
This case is a reminder that:
- Immune cells influence not just the disease, but also how our therapies behave.
- Understanding these shifts allows us to better predict treatment response and potential risks.
- Advanced immune profiling is becoming essential for personalised, safer patient care.
The immune system doesn’t just reflect the illness—it helps tell the story of the treatment!!”
More posts featuring Immune System.